ECHA have launched a consultation on its 12th draft recommendation of substances to be added to the REACH authorisation list (Annex XIV). Currently, the substances included in the draft recommendation are:
- Melamine (EC-No.: 203-615-4; CAS: 108-78-1)
- Bis(2-ethylhexyl) tetrabromophthalate covering any of the individual isomers and/or combinations thereof (TBPH) (EC-No: n/a; CAS: n/a)
- S-(tricyclo[5.2.1.0 2,6]deca-3-en-8(or 9)-yl) O-(isopropyl or isobutyl or 2-ethylhexyl) O-(isopropyl or isobutyl or 2-ethylhexyl) phosphorodithioate (EC-No.: 401-850-9; CAS: 255881-94-8)
- Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (EC-No.: 278-355-8; CAS: 75980-60-8)
- Barium diboron tetraoxide (EC-No. 237-222-4; CAS: 13701-59-2)
Along with this, ECHA (on behalf of the European Commission) are also collecting input for a call for evidence on the socio-economic impacts an inclusion of these substances in the Authorisation List would have (please check this questionnaire). The deadline for both the consultation and call for evidence is 7 May 2024.
Next steps:
ECHA’s Member State Committee (MSC) will form an opinion on this draft recommendation, taking into account the input provided to the consultation/call for evidence. Based on the MSC opinion, ECHA will then finalise its recommendation and send it to the European Commission for decision making. The finalization of the ECHA recommendation is expected to take place in spring 2025. Once a substance is finally included by the Commission in the REACH Authorisation List (Annex XIV), it cannot be placed on the market or used after a specified date, unless an authorisation is granted for a specific use (for which companies can apply).
BIVDA members who are using these substances are requested to provide feedback to regulatory@bivda.org.uk asap.
This information is kindly provided by MedTech Europe.
